Summary of use during lactation
No information is available on the clinical use of atogepant during breastfeeding. However, amounts in breastmilk are low and virtually absent from milk 16 hours after a dose. Atogepant would not be expected to cause any adverse effects in breastfed infants. If atogepant is required by the mother of an older infant, it is not a reason to discontinue breastfeeding, but until more data become available, an alternate drug may be preferred while nursing a newborn or preterm infant.
Drug levels in milk and infant serum
Maternal Levels. Twelve healthy lactating adult women 1 to 6 months postpartum were given a single 60 mg oral dose of atogepant in a multicenter study. Milk samples were collected prior to the dose and over the following intervals: 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 16, and 16 to 24 hours after the dose. The average peak milk level occurred at an average of 2 hours (range 1 to 3 hours) and averaged 75 mcg/L. A total of 9 mcg was excreted into milk over the collection period and the calculated relative infant dose averaged 0.19%.[1] Infant Levels. Relevant published information was not found as of the revision date.
Effects in breastfed infants
Relevant published information was not found as of the revision date.
Effects on lactation and breastmilk
Relevant published information was not found as of the revision date.
Alternative drugs to consider
(Migraine Prophylaxis) Divalproex, Erenumab, Metoprolol, Nortriptyline, Propranolol, Topiramate, Valproic Acid; (Migraine Treatment) Eletriptan, Rizatriptan, Sumatriptan, Zolmitriptan
Source: Drugs and Lactation Database (LactMed®), National Institute of Child Health and Human Development, NCBI Bookshelf. Check LactMed for the most recent revision.
Medical disclaimer: This page is for qualified healthcare professionals and is a decision-support aid only. It does not replace clinical judgement, local protocols or product information. Verify every dose and threshold before use. See the full Medical Disclaimer.